Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.
Saved in:
| Title: | Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. |
|---|---|
| Authors: | Valantin MA (AUTHOR), Bittar R (AUTHOR), de Truchis P (AUTHOR), Bollens D (AUTHOR), Slama L (AUTHOR), Giral P (AUTHOR), Bonnefont-Rousselot D (AUTHOR), Pétour P (AUTHOR), Aubron-Olivier C (AUTHOR), Costagliola D (AUTHOR), Katlama C (AUTHOR), TOTEM trial group (CORPORATE AUTHOR), Valantin, M A1 (AUTHOR), Bittar, R (AUTHOR), de Truchis, P (AUTHOR), Bollens, D (AUTHOR), Slama, L (AUTHOR), Giral, P (AUTHOR), Bonnefont-Rousselot, D (AUTHOR), Pétour, P (AUTHOR) |
| Source: | Journal of Antimicrobial Chemotherapy (JAC). Mar2010, Vol. 65 Issue 3, p556-561. 6p. |
| URL: | 48045047 |
| Database: | Environment Complete |
Be the first to leave a comment!
